Neurocrine Biosciences INC: directors' dealings · United States · SEC (Form 4)

About Neurocrine Biosciences INC

Neurocrine Biosciences Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States, with corporate headquarters in San Diego, California. The company was founded in 1992 by Wylie Vale, Ph.D. of the Salk Institute and Lawrence Steinman, Ph.D. of Stanford University. From the outset, Neurocrine has been built around neuroscience-driven drug discovery, with a mission focused on underserved patient populations and difficult-to-treat diseases. Neurocrine’s business model combines research, clinical development, and commercialization of specialty medicines. Its core therapeutic focus spans neurological, psychiatric, endocrine, and immunological disorders. The company already has a meaningful commercial franchise and a deeper clinical pipeline, which gives it a hybrid profile: part established product company, part development-stage innovator. Among its approved medicines are INGREZZA, used in certain movement disorders linked to dopamine regulation, and CRENESSITY, approved for classic congenital adrenal hyperplasia. Neurocrine also participates in strategic collaborations that can generate royalties or expand the reach of its scientific platform. From a competitive standpoint, Neurocrine is best viewed as a focused specialist rather than a broad-based large-cap pharma group. Its strengths lie in deep domain expertise in neuroscience, disciplined clinical execution, and an ability to convert scientific insights into approved therapies. That focus can be a source of differentiation and pricing power, but it also means the company depends heavily on a limited number of commercial assets and the success of a relatively concentrated pipeline. For investors, this creates a mix of upside optionality and product-concentration risk. Geographically, the company remains primarily centered on the United States, which is both its main operating base and its key commercial market. Its R&D and clinical programs, however, may extend beyond domestic boundaries through trials, regulatory work, and collaboration structures. Neurocrine continues to emphasize rare and under-addressed diseases, especially in areas where it believes it can meaningfully shift standards of care. Recent highlights underscore that strategic direction. In 2025 and 2026, Neurocrine continued to release quarterly financial results, publish its 2025 annual report, and present new clinical data, including phase 2 findings for osavampator in major depressive disorder and CAH registry analyses related to classic congenital adrenal hyperplasia. Overall, the company’s recent news flow supports a clear investment narrative: defend and grow its commercial base while advancing a pipeline that could broaden long-term value creation on the NASDAQ in the United States.